Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varlilumab - Celldex Therapeutics

Drug Profile

Varlilumab - Celldex Therapeutics

Alternative Names: CDX-1127

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD27 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I/II Renal cell carcinoma
  • Phase I Glioma
  • No development reported Haematological malignancies; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 09 Sep 2019 Rutgers and National Cancer Institute plan a phase I trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT04081688)
  • 21 Aug 2019 Celldex Therapeutics suspends patient enrolment in a phase II trial in Glioblastoma in USA due to pending new testing requirements from the FDA (IV) (NCT03688178)
  • 08 Aug 2019 Celldex Therapeutics and University of Virginia re-initiates the phase I/II Mel-65 trial for Malignant melanoma (Combination therapy, Late-stage disease, Inoperable/Unresectable) in USA (IV) (NCT03617328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top